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ABSTRACT
Fibroblast growth factor 1 (FGF1) is involved in
muscle development and regeneration. The FGF1
gene contains four tissue-specific promoters allow-
ing synthesis of four transcripts with distinct leader
regions. Two of these transcripts contain internal
ribosome entry sites (IRESs), which are RNA ele-
ments allowing mRNA translation to occur in condi-
tions of blockade of the classical cap-dependent
mechanism. Here, we investigated the function and
the regulation of FGF1 during muscle differentiation
and regeneration. Our data show that FGF1 protein
expression is induced in differentiating myoblasts
and regenerating mouse muscle, whereas siRNA
knock-down demonstrated FGF1 requirement for
myoblast differentiation. FGF1 induction occurred
at both transcriptional and translational levels,
involving specific activation of both promoter A
and IRES A, whereas global cap-dependent transla-
tion was inhibited. Furthermore, we identified, in
the FGF1 promoter A distal region, a cis-acting ele-
ment able to activate the IRES A-driven translation.
These data revealed a mechanism of molecular
coupling of mRNA transcription and translation,
involving a unique process of IRES activation by
a promoter element. The crucial role of FGF1 in
myoblast differentiation provides physiological
relevance to this novel mechanism. This finding
also provides a new insight into the molecular
mechanisms linking different levels of gene expres-
sion regulation.
INTRODUCTION
The ﬁbroblast growth factor 1 (FGF1 or aFGF) is a
member of the heparin-binding growth factor family of
proteins with mitogenic, angiogenic, mesoderm-inducing
and neurectoderm-modulating activities. FGF1 belongs
to the FGF family currently composed of 22 members
which have important roles in embryogenesis and diﬀer-
entiation in organisms as diverse as Xenopus laevi and
mammals (1,2). FGFs (especially FGF1 and FGF2) are
classically considered as mitogens behaving as inhibitors
of myoblast diﬀerentiation (3). However, intracellular
FGF1 has been described as a myoblast diﬀerentiation
activator (4). Furthermore, although it has been proposed
as a negative regulator of muscle development, elevated
levels of FGF1 have been observed in regenerating muscle
cells of dystrophin-deﬁcient mice (mdx) (5) and in
Facioscapulohumoral muscular dystrophy patients (6).
Thus, FGF1 is clearly implicated in myogenesis and
muscle regeneration, but its role in muscle development
is complex and involves non-elucidated mechanisms.
The fgf1 gene, expressing a single protein isoform,
has four alternative tissue-speciﬁc promoters designed A
to D and is subjected to a process of alternative splicing
conserved among mammals (7,8). Transcription results in
mRNAs diﬀering by their 50 untranslated region (50UTR)
(Figure 2A). Thus, each promoter leads to synthesis of an
mRNA containing a distinct 50 untranslated exon, sug-
gesting speciﬁc translational regulation of FGF1 expres-
sion by such 50UTRs as a consequence of the promoter
usage.
Translation in mammalian cells is mainly regulated at
the initiation step through the rate-limiting recruitment
of ribosomes to mRNA (9). Translation initiation can
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The former is mediated by the mRNA 50cap structure and
represents the standard mode of translation used by most
cellular mRNAs. It is predominantly controlled by the
availability of the eukaryotic initiation factor 4F
(eIF4F), comprised of the 50cap binding protein eIF4E,
the scaﬀold protein eIF4G and an ATP-dependent heli-
case eIF4A (10). eIF4E availability for eIF4F formation is
modulated by sequestration by eIF4E-binding proteins
(4E-BPs) (11). The most abundant, 4E-BP1, is inactive
when hyperphosphorylated by the kinase mTOR and acti-
vated when mTOR activity is reduced (12,13).
Cap-independent translation is mostly mediated by
mRNA structural elements called IRESs (Internal
Ribosomal Entry Sites) (14). IRESs are able to recruit
ribosomes either by themselves or with the help of cellular
proteins called ITAFs (IRES trans-acting factors) (15).
IRESs have been identiﬁed in several mammalian
mRNAs, mainly in control genes such as growth factors
or transcription factors (16). IRESs allow translation of
such mRNAs when cap-dependent translation is blocked
in conditions of stress or during mitosis (12,17). However
they also allow a subtle regulation of mRNA translation
in pathological and physiological situations such as hyper-
glycemia, hormone stimulation, ischemia or brain devel-
opment (18–21). We have identiﬁed IRESs in the FGF1
50UTRs A and C (Figure 2A) (22).
Fgf1 gene expression is strictly regulated during devel-
opment and in adulthood (23). Surprisingly, little is
known about the molecular mechanisms regulating its
expression. While poorly expressed in adult tissues, it
can become overexpressed in some pathophysiological
situations such as during muscle regeneration (5). Here,
we demonstrate that the FGF1, required for myoblast
diﬀerentiation, is induced during this process as well as
in regenerating muscle by a novel mechanism of coupled
transcription and translation involving FGF1 promoter
A and IRES A.
MATERIALS AND METHODS
Plasmids
Plasmids (P1A-luc, P1B-luc, P1C-luc and P1D-luc)
used to measure promoter activities were kindly provided
by Dr I.M. Chiu. Plasmids with EMCV and FGF1 IRESs
were pCREL, pCRF1AL, pCRF1BL, pCRF1CL and
pCRF1DL (22,24). CMV promoter was replaced in
pCREL and pCRF1AL FGF1 promoter A ampliﬁed
from plasmid P1A-luc. For P1A, P1A 1–391 and P1A
1–682 containing bicistronic constructs, -globin intron,
LucR and FGF1 IRES A were inserted in pGL4.12
(Promega, France) downstream from full length or deleted
FGF1 promoter A.
Plasmid construction details are available upon request.
Cell culture
C2C12 myoblasts were maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) with 20% fetal calf serum
in 100-mm diameter dishes at 378C with 5% CO2.
For diﬀerentiation, cells were changed into fusion
medium (DMEM with 5% horse serum).
Transient transfections were performed in 12-well
dishes using 0.5mg of plasmid with FuGene-6 (Roche
Molecular Biochemicals, Mannheim, Germany) and
Optimem (Gibco-BRL, Invitrogen, Paisley, United
Kingdom).
Small interference RNAs were from Dharmacon
siGENOME SMARTpool FGF1 siRNA,
siGENOME SMARTpool eIF4E siRNA and
siGENOME non-targeting siRNA. C2C12 cells were
transfected with 20nM siRNA with Hyperfect transfec-
tion reagent (Qiagen).
Mouse muscle regeneration model
Twenty-ﬁve microliters of cardiotoxin (Latoxan) at
10mM, were injected in Tibialis anterior (TA) muscle of
4-week-old female C57BL/6J mice to induce degeneration
and regeneration (25). Non-injected TA muscles were used
as control.
Two days after cardiotoxin treatment, TA muscles were
injected with 50mg of plasmid (25ml ﬁnal volume). Three
days later, TA muscles were removed and stored at –808C.
Ethics statement
All procedures were performed in conformity with the
guidelines of the company’s local ethics committee and
in accordance with the recommendations of the
European Accreditation of Laboratory Animal Care
Institute. The animal facility (directed by Yara Barreira)
has obtained the animal experimentation agreement
No B31-555-7.
RNA extraction and real time RT–qPCR
Total RNA was isolated from C2C12 cells using GenElute
Mammalian Total RNA kit (Sigma-Aldrich Chimie).
After DNase I treatment (DNase I Ampliﬁcation Grade,
Invitrogen), reverse transcription was performed with the
High capacity cDNA Archive Kit (Applied Biosystems,
Foster City, CA). As an internal control, ribosomal L8
(mRL8) RNA was used.
Quantitative PCR was performed on an ABI 7900
sequence detection system (Applied Biosystems) using
Sybr Green PCR Master Mix (Applied Biosystems) for
detection of FGF1 (all transcripts), FGF1A and RL8
transcripts.
Primer sequences are available upon request.
Reporter assays
Muscles and C2C12 cells were ground in Passive Lysis
Buﬀer (Promega) using an Ultra-Turrax T25 (Janke and
Kunkel, IKA Labortechnik). Quantiﬁcation of biolumi-
nescence was realised with a luminometer (Centro
LB960, Berthold) using the Dual-Luciferase Reporter
Assay (Promega, France).
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bioluminescence data
In vivo imaging was performed with a cooled CCD camera
(1394 ORCA II, Hamamatsu Photonics) using mice trans-
duced with a bicistronic AAV vector expressing the Fireﬂy
luciferase under control of FGF1 IRES A, as previously
described (26). Eighteen days after transduction, muscles
were cardiotoxin-treated and imaged 3 and 7 days later.
Prior to imaging, mice were anesthetized by intraperito-
neal injection of Ketamine (12.5mg/ml) and Xylazine (1%)
solutions (10ml/g body weight). D-luciferin was injected
intraperitoneally (50mg/g BW, Luciferin-EF
TM, Promega
France), 5min before measurement of photon emission.
Grey scale images and bioluminescence color images
were superimposed using the Simple PCI software
(Hamamatsu Photonics). Light output was quantiﬁed as
the mean grey level per second of time exposure and per
region of interest (ROI).
Western blotting
Muscles were homogenized and western blots performed
as previously (19).
Primary antibodies were rabbit polyclonal antibodies
against FGF1 (F5521, Sigma, 1/500), eIF4E (Cell
Signaling, 1/10000), 4E-BP (Cell Signaling, 1/1500) and
mouse monoclonal antibodies against myogenin (F5D,
Santa Cruz Biotechnologies, 1/400), Glyceraldehyde
3-phosphate dehydrogenase (GAPDH, Santa Cruz
Biotechnologies, 1/200), b-tubulin (Sigma, 1/4000).
Secondary antibodies were peroxidase-conjugated-
AﬃniPure Donkey Anti-Rabbit IgG and -AﬃniPure
Donkey Anti-Mouse IgG (Jackson ImmunoResearch,
Baltimore, 1/20000).
Protein detection was carried out using Supersignal
West Femto Maximum Sensitivity Substrate,
SuperSignal West Pico Chemiluminescent Substrate and
ECL western blotting substrate (ThermoScientiﬁc, USA).
Analysis of 4E-BP1-eIF4E interaction
Cells were harvested in lysis buﬀer [25mM Tris–HCl pH
7.4, 50mM KCl, 5% glycerol, 0.5% Nonidet P-40 and
1mM DTT supplemented with protease inhibitor mix-
tures (Roche)] and clariﬁed by centrifugation at
12000rpm for 10min at 48C. Proteins from the superna-
tant were quantiﬁed using the Bradford method (Bio-
Rad). After preclearing cell lysates with 10ml of Protein
G-Agarose conjugate beads for 1h at 48C, 50mg of protein
were incubated with 10ml of eIF4E antibody agarose
conjugate (Santa Cruz Biotechnology) overnight at 48C.
Beads were washed ﬁve times with lysis buﬀer and immu-
noprecipitated proteins eluted with Laemmli sample buﬀer
and subjected to immunoblot analysis.
Statistical analysis
Statistical analysis was performed with Prism (GraphPad
Software Inc.). Unpaired t-tests (two-tailed) were realized
to detect signiﬁcant diﬀerences between group means. The
level of signiﬁcance was set at P<0.05.
RESULTS
FGF1 is induced during myogenesis and required for
myoblast differentiation
Treatment of skeletal muscle with the snake venom cardi-
otoxin (CTX) has been described to induce severe
myonecrosis and subsequent muscle regeneration while
leaving the innervating nerve intact (25,27). We used this
approach to study FGF1 expression in regenerating mus-
cles. We observed that the FGF1 protein level started to
increase 3 days after cardiotoxin injection and continued
to rise after 7 days. The early induction of FGF1 at Day 3
was concomitant with the expression of myogenin, a
speciﬁc marker of myotubes (Figure 1A).
In order to determine whether FGF1 induction is con-
nected to myoblast diﬀerentiation, we used the murine
myoblast C2C12 cell line which can be induced to diﬀer-
entiate into myotubes by serum-deprivation (28). We
observed that FGF1 starts to accumulate in C2C12 cells
after 2 days of serum-deprivation, when myoblasts begin
to diﬀerentiate into myotubes, as visualized by myogenin
expression (Figure 1B).
To evaluate the importance of intracellular FGF1
during myoblast diﬀerentiation, we knocked down its
expression in C2C12 cells by siRNA transfection experi-
ments. FGF1 knock-down in the early-diﬀerentiation
stages prevented the strong myogenin induction observed
at Days 2 and 3 with the control siRNA (Figure 1C).
A smaller induction of myogenin was observed later, at
Day 4, concomitantly with an increase of FGF1 expres-
sion indicating that FGF1 knock-down was temporary
(Figure 1C, right panel).
Myotube formation was observed from Day 2 to Day 5
(Figure 1D). Strikingly, the C2C12 cell aspect was already
diﬀerent at Day 3, since the FGF1 knock-down resulted in
anarchical cell layout. Furthermore, this phenotype was
aggravated at Days 4 and 5 when formation of myotubes
occurred. Indeed, these myotubes appeared irregular and
abnormal.
These results showed that FGF1 is induced during
muscle diﬀerentiation/regeneration and required for cor-
rect myoblast diﬀerentiation into myotubes. FGF1 knock-
down did not prevent myotube formation, but resulted in
an anarchical cell layout starting from Day 3 of myoblast
diﬀerentiation.
The FGF1 promoter A is strongly activated during
myogenesis
To investigate the mechanism of FGF1 induction during
myoblast diﬀerentiation, quantitative real-time RT–PCR
(RT–qPCR) analysis was performed to detect the endo-
genous FGF1 mRNA. Data showed that the total level of
FGF1 mRNAs increased 9-fold at Day 2 of diﬀerentiation
(Figure 2B). The level of transcript A followed the same
pattern of induction with a 35-fold increase, suggesting
a main contribution of promoter A to FGF1 mRNA
induction (Figure 2A and C).
To conﬁrm this hypothesis, activities of the four FGF1
promoters were evaluated using gene reporter assay
(Figure 2A and Figure 3). The enzymatic activity of
Nucleic Acids Research, 2009,Vol.37, No. 16 5269Fireﬂy luciferase (LucF) expressed under the control of
each FGF1 promoter was measured in proliferating and
diﬀerentiating C2C12 cells. Data showed a 41-fold
increase of promoter A activity at Day 2, whereas pro-
moter B showed a 3-fold increase (Figure 3A and
Supplementary Table I). Regarding promoter C, its activ-
ity diminished, while promoter D was always very weak
(Supplementary Table I). In contrast to the endogenous
transcript A which showed a peak of accumulation at
D2, the reporter assay revealed a continuous activation
of the promoter A, reaching a 160-fold activation when
diﬀerentiation into myotubes was completed at Day 5
(Figure 3A and Supplementary Table 1). Such a discrep-
ancy could result from a diﬀerence of mRNA stability
regulation, as the endogenous transcript, but not the
reporter transcript, bears a 1700-nt long 30 UTR.
We then studied the promoter A activity and the FGF1
endogenous mRNA levels in vivo, during muscle regenera-
tion. Plasmids expressing LucF under the control of
the promoter A or the ubiquitous cytomegalovirus
(CMV) promoter were injected into cardiotoxin-treated
or untreated muscles of wild-type mice. We observed a
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Figure 1. FGF1 expression and knock-down during myogenesis. (A) FGF1 accumulation in mouse regenerating muscles. Western blot analysis was
performed using anti-FGF1, anti-myogenin and anti-GAPDH antibodies, on untreated (NT) or treated Tibialis anterior muscles, 3, 5 and 7 days
(D3, D5 and D7, respectively) after cardiotoxin (CTX) injection. Muscle No1 and 2 correspond to two diﬀerent individuals. Myogenin was used as a
marker of myoblast diﬀerentiation. GAPDH was used as a normalization control. These data correspond to a representative experiment (repeated at
least three times). (B) FGF1 accumulation during C2C12 myoblast diﬀerentiation. Western blot analysis was performed as in A on proliferating (P)
and diﬀerentiating myoblasts from Day 1 (D1) to Day 5 (D5) after serum-starvation treatment. These data correspond to a representative experiment
(repeated ﬁve times). (C) Eﬀect of FGF1 knock-down on myoblast diﬀerentiation. C2C12 cells were transfected with siRNA against FGF1 (siFGF1)
or siRNA control (siControl). Western blot was performed as above on proliferating (P) and diﬀerentiating myoblasts (D2–D5). These data
correspond to a representative experiment (repeated at least three times). (D) Eﬀect of FGF1 knock-down on myotube formation. C2C12 cells
were transfected with siRNA against FGF1 (siFGF1) or siRNA control (siControl) and myotube formation was followed by contrast phase
microscope analysis. These data correspond to a representative experiment (repeated three times).
5270 Nucleic Acids Research, 2009, Vol. 37,No. 16signiﬁcant 1.5-fold increase of promoter A activity 5 days
after CTX-treatment relatively to untreated muscles, while
no change of the CMV promoter activity could be
detected (Figure 3B). RT–qPCR analysis of the endogen-
ous transcript A in CTX-muscle indicated a 2.4-fold
increase at Day 3, which remained stable until Day 7,
whereas the total FGF1 mRNA did not signiﬁcantly
increase (Figure 3C).
These results, although showing diﬀerences between the
levels of FGF1 mRNAs and promoter activation observed
in vivo and in vitro, were concordant by revealing the
induction of the FGF1 promoter A in both diﬀerentiating
myoblast and regenerating muscle.
Cap-dependent translation decreases during myoblast
differentiation
To determine whether FGF1 expression during myoblast
diﬀerentiation involved cap- or IRES- dependent transla-
tion, we looked at the status of global cap-dependent
translation during myoblast diﬀerentiation by analyzing
4E-BP1 and eIF4E expression, and monitoring eIF4E
sequestration by 4E-BP1.
Western blot experiments performed on protein extracts
from proliferating and diﬀerentiating myoblasts showed
that the expression level of eIF4E and 4E-BP1 did not
vary whatever the diﬀerentiation state (Figure 4A).
However, changes in 4E-BP1 gel mobility were visible
with a prominent modiﬁcation at Day 2 of diﬀerentiation.
4E-BP1 protein is known to exhibit a complex gel mobility
pattern due to post-translational modiﬁcations including
diﬀerent degrees of phosphorylations. Other post-
translational modiﬁcations that can render 4E-BP1 data
analysis even more complex are that the phosphorylated
protein can be ubiquitinated (29). Furthermore, phos-
phorylation at sites initially considered as important for
4E-BP1 dissociation from eIF4E may not aﬀect directly
4E-BP1 aﬃnity for eIF4E, but may serve instead as
priming events for another type of a yet unknown post-
translational modiﬁcation that is actually required for
4E-BP1 dissociation from eIF4E (30). Therefore,
we directly tested whether modiﬁcations in 4E-BP1 elec-
trophoretic properties were correlated to changes in
4E-BP1 aﬃnity for eIF4E by co-immunoprecipitation
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Figure 3. Activities of FGF1 promoters during myoblast diﬀerentiation
and muscle regeneration. (A) Activities of FGF1 promoters A and B
during C2C12 myoblast diﬀerentiation. Luciferase activities were mea-
sured on C2C12 cells transfected with plasmids containing the Fireﬂy
luciferase expressed under the control of the FGF1 promoter A or B.
Results are expressed relatively to the proliferation state. The graphs
show the mean SEM of ﬁve independent experiments. (B) Activities
of FGF1 promoter A and CMV promoter during mouse muscle regen-
eration. Plasmids expressing the Fireﬂy luciferase under the control of
FGF1 promoter A or CMV promoter were injected into the Tibialis
anterior muscles of wild-type mice. Luciferase activities were measured
on cardiotoxin-treated (+) or untreated ( ) muscles at Day 5 after
CTX treatment. Results are expressed relatively to the level of
untreated muscle and represent mean SEM. n, number of muscles,
 P<0.05. (C) RT qPCR quantiﬁcation of endogenous FGF-1 mRNA
and of the transcript A standardized to mRL8 RNA in untreated or
cardiotoxin treated muscle extracts (Days 3 and 7). Results are
expressed relative to the level of untreated muscle and represent
mean   SEM of two independent experiments.
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Figure 2. Transcriptional regulation of endogenous FGF1 expression
during myoblast diﬀerentiation. (A) Schema of the FGF1 gene struc-
ture. The gene structure is presented with a scale (kbp). Exons –1A,
–1B, –1C and –1D are the alternative exons generated by the use of
promoters A, B; C and D, respectively. The four corresponding
mRNAs, with diﬀerent 50 UTRs A, B, C and D, respectively, are
represented below. Transcripts A and C contain IRESs (IRES A and
IRES C, respectively). (B) and (C) RT qPCR quantiﬁcation of endo-
genous FGF-1 mRNA (B) and of the transcript A (C) standardized to
mRL8 RNA in proliferating and diﬀerentiating C2C12 myoblasts.
Results are expressed relative to the level of proliferating cells and
represent mean SEM of at least three independent experiments.
Nucleic Acids Research, 2009,Vol.37, No. 16 5271experiments. The data revealed a transient increase in
the formation of the 4E-BP1/eIF4E complex from Day 1
to Day 3 and peaking at Day 2 of diﬀerentiation
(Figure 4B). These results indicated that eIF4E was tran-
siently sequestered by 4E-BP1 through the process of
myoblast diﬀerentiation.
FGF1 mRNA translation is induced through an IRES
A-dependent mechanism during myoblast differentiation
and muscle regeneration
We have shown above that FGF1 protein induction starts
at Day 2 of myoblast diﬀerentiation, concomitantly with a
peak of promoter A activity and a transient decrease of
cap-dependent translation. The presence of an IRES in
transcript A, appearing as mainly responsible for FGF1
induction, suggested that FGF1 mRNA translation could
occur by an IRES-dependent mechanism (22). This
hypothesis was assessed by measuring FGF1 protein
expression in diﬀerentiating C2C12 cells treated with an
eIF4E-targeted siRNA (sieIF4E) or a control siRNA
(siControl) (Figure 5A and B). The eIF4E knock-down
did not aﬀect the FGF1 induction at Day 2, suggesting
that its expression is mediated by a cap-independent mech-
anism (Figure 5B, right panel).
IRES activities in the 50UTR of FGF1 mRNAs were
measured using bicistronic constructs expressing the
Renilla (LucR) and Fireﬂy luciferases in a cap- and
IRES-dependent manner respectively (Figure 5C) (22).
Consequently, the ratio of LucF to LucR activities
is expected to reﬂect the relative level of IRES- to cap-
dependent translation. We observed a transient increase
of LucF activity (2.5-fold) and of the ratio LucF/LucR
peaking at Day 2 after the induction of diﬀerentiation,
with the construct containing the transcript A 50UTR,
thus the IRES A (Figure 5C and Supplementary
Table II). No relative increase of IRES activities
was detected in the 50UTRs of transcript B or D, while
the UTR C containing the IRES C also showed a small
peak of activity (but not statistically signiﬁcant) at Day 2
of FGF1 during myoblast diﬀerentiation (Supplementary
Table II). In addition, the equivalent amount of lucR and
lucF RNA conﬁrmed that all the mRNAs were bicistronic
(Supplementary Figure S1 and data not shown). These
data showed that the IRES A is the only one to be sig-
niﬁcantly activated at Day 2 of diﬀerentiation.
In order to check IRES A involvement in FGF1 induc-
tion during myogenesis in vivo, FGF1-based bicistronic
rAAVs (adeno-associated virus) containing the expres-
sion cassette described in Figure 5C were injected into
CTX-treated or untreated muscles of wild-type mice.
The IRES-driven LucF expression was followed on live
animals, using a CCD bioluminescence camera. LucF
was measured during 7 days and quantiﬁed at Days 3
and 7 after CTX-treatment. A weak increase of the
IRES A activity was observed at Day 3, which became
signiﬁcant at Day 7 with a 2.5-fold increase measured in
CTX-treated-muscles relatively to untreated muscles
(Figure 6A and B). Measurement of LucR and LucF
activities in muscle extracts at Day 5 after CTX-treatment
conﬁrmed such a signiﬁcant augmentation of the FGF1
IRES A activity (Figure 6C, left panel), whereas the activ-
ity of the EMCV (EncephaloMyoCarditis Virus) IRES,
used as a control, remained unchanged (Figure 6C, right
panel).
These results highlighted the speciﬁc activation of the
IRES A of FGF1 during myoblast diﬀerentiation and
muscle regeneration. Furthermore they provided new
insight into the mechanisms of FGF1 synthesis by show-
ing that it is expressed by IRES-dependent mechanism
in the early stage of myoblast diﬀerentiation, when the
cap-dependent translation is inhibited.
The FGF1 IRES A is activated by a cis-acting element
present in the promoter A
Our data showed that the IRES A activation is concom-
itant with the activation of the FGF1 promoter A. This
observation, together with previous data indicating that
the IRES activity may be inﬂuenced by the promoter
(Y. Martineau, PhD thesis 2004), raised the hypothesis
of a mechanism of transcription-translation coupling.
In order to investigate the physiological relevance of
such a correlation and the putative functional link
between promoter and IRES, we replaced the CMV pro-
moter by the FGF1 promoter A upstream from the bicis-
tronic cassette containing either the FGF1 IRES A or the
EMCV IRES (Figure 7A). The bicistronic constructs with
either FGF1 or CMV promoter were used to transfect
C2C12 cells as above. IRES activities are presented as
the LucF/LucR ratio, thus normalized to the mRNA
level reﬂected by LucR. As shown in Figure 7B, the
FGF1 IRES activity at Day 2 was 15-fold superior for
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Figure 4. Regulation of the cap-dependent translation during myoblast
diﬀerentiation. (A) Western blot analysis of eIF4E and its inhibitor 4E-
BP during myoblast proliferation (P) and diﬀerentiation (D), using
anti-eIF4E and anti-4E-BP antibodies, respectively. b-tubulin was
used as a normalization control. These data correspond to a represen-
tative experiment (repeated at least three times). (B) Co-immunopreci-
pitation of eIF4E and 4E-BP during myoblast proliferation (P) and
diﬀerentiation (D). Immunoprecipitation was performed on C2C12
cell extracts with an antibody against eIF4E. The bound and the
unbound fractions were applied to Tris–Tricine SDS–PAGE followed
by Western transfer and immunodetection with antibodies as indicated.
These data correspond to a representative experiment (repeated three
times).
5272 Nucleic Acids Research, 2009, Vol. 37,No. 16the construct containing the FGF1 promoter A compared
to the one obtained with the CMV promoter. In contrast,
the EMCV IRES activity was similar in the presence of
either promoter A or CMV promoter (Figure 7C).
These data also showed that the peak of IRES A
activation at Day 2 of diﬀerentiation occurs with both
promoters and is speciﬁc. However, the presence of the
FGF1 promoter renders the FGF1 IRES as active as the
EMCV IRES in proliferating cells and largely superior to
the EMCV IRES in diﬀerentiating cells.
In order to map the region of the FGF1 promoter A
responsible for the IRES activation, the promoter was
deleted of nt 1–392 or nt 1–682 (Figure 7A). The LucR
activity of the corresponding constructs clearly showed
that the region between nt 1 and 392 contains an element
necessary for transcriptional activation at the FGF1 pro-
moter A at Day 2 and later (Figure 7D). Furthermore, the
IRES A-dependent translation (LucF/LucR ratio) peaked
at Day 2 with the complete promoter, but not with the
deleted constructs (Figure 6E).
In conclusion, our results clearly show that FGF1 IRES
A-dependent translation is strongly activated in the pres-
ence of the promoter A, and that this activation requires a
cis-acting element localized between nt 1 and 392 of the
promoter.
DISCUSSION
In this study, we have investigated the molecular mecha-
nisms implicated in the induction of FGF1 expression
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Figure 5. IRES-dependent expression of FGF1 during myoblast diﬀerentiation. (A) Control of eIF4E knock-down. Proliferating C1C12 cells were
transfected with an siRNA against eIF4E (sieIF4E) and siRNA control (sicontrol), in conditions described in ‘Materials and Methods’ section, and
submitted to serum starvation. eIF4E level following siRNA treatments was analyzed on the same gel by western blot at Day 1 of diﬀerentiation. (B)
Eﬀect of eIF4E knock-down on FGF1 expression during myoblast diﬀerentiation. C2C12 cells were transfected with sieIF4E or sicontrol as above.
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to evaluate IRES activities is schematized. The bicistronic cassette expresses, under the control of the CMV (Cytomegalovirus) promoter, Renilla
(LucR) and Fireﬂy (LucF) luciferase reporter genes in a cap- and IRES-dependent manner, respectively. The bicistronic cassette contains the FGF1
mRNA 50 UTRs A or B. Renilla and Fireﬂy luciferase activities were measured on extracts of C2C12 cells transfected with the indicated bicistronic
expression vectors. Relative LucR (cap-dependent) and LucF (IRES-dependent) activities are shown for the diﬀerent diﬀerentiation days (Days 1–5),
normalized to the activities obtained in proliferation (P). The graphs show the mean SEM of ﬁve independent experiments;
  P<0.01.
Nucleic Acids Research, 2009,Vol.37, No. 16 5273during myogenesis. We demonstrate that FGF1
up-regulation is required for myoblast diﬀerentiation
and results from a concomitant and speciﬁc activation
of both FGF1 promoter A and IRES A, when the
cap-dependent translation is blocked, in diﬀerentiating
myoblasts as well as in regenerating mouse muscle.
Furthermore, our data show that the IRES A-dependent
translation is strongly activated in the presence of the
FGF1 promoter A, revealing a novel mechanism of
coupled translation and transcription.
FGF1 has a double role in myogenesis
FGF1 induction during muscle regeneration is concomi-
tant with the apparition of myotubes. Furthermore, our
data clearly show that FGF1 knock-down attenuates the
myogenin induction peaking at Day 2 and generates for-
mation of abnormal myotubes. This observation could
seem discordant with the known function of FGFs as
myoblast diﬀerentiation inhibitors (3,31). However
FGF1, in contrast to other members of the FGF family,
Figure 6. Regulation of FGF1 IRES A-driven translation activity during muscle regeneration. (A) Kinetics of the expression of luciferase Fireﬂy
under the control of the IRES A during muscle regeneration. The luciferase Fireﬂy activity was measured in mice transduced with a bicistronic AAV
vector containing the gene-encoding LucF under the control of the IRES A of FGF1 (10
10 total particles/muscle). Mice were imaged using a
bioluminescent camera after injection of D-luciferin intraperitonealy. The Fireﬂy luciferase activities are shown in pseudocolors at Days 3 and 7 after
cardiotoxin treatment. The color scale illustrates the variation of luciferase activities from maximum (red) to minimum (dark blue). (B) Luminescent
measurement of luciferase Fireﬂy activities with CCD camera in the experiments described in (A). Each dot of the graph represents one muscle and
the mean is indicated by a short line. (C) Speciﬁc activation of the FGF1 IRES A during muscle regeneration. Plasmids expressing the Renilla and
Fireﬂy luciferases through a cap- and IRES-dependent mechanisms respectively were injected into the Tibialis anterior muscles of wild-type mice.
Luciferase activities were measured 5 days after intra-muscular injection of cardiotoxin. IRES activities are given as the LucF/LucR ratio relatively to
the level of untreated muscles and represent mean   SEM. n, number of muscles,
   P<0.001.
5274 Nucleic Acids Research, 2009, Vol. 37,No. 16is expressed in dystrophic muscle, suggesting a positive
role in the regeneration of skeletal muscle ﬁber (5,6).
The double role of FGF1 as a proliferation activator as
well as a diﬀerentiation inducer may result from its diﬀer-
ent functions as an extracellular or intracellular factor (4).
Extracellular FGF1 would activate myoblast proliferation
by activating the FGF-signaling pathway mediated by
FGFR1 receptor upregulated in proliferating myoblasts,
(32). In contrast, intracellular FGF1 would act on diﬀer-
entiation by an intracrine pathway. Alternatively, the dif-
ferent roles of FGF1 could be due to diﬀerential
expression of FGF receptors (33). FGFR1 and FGFR4
Figure 7. Eﬀect of the FGF1 promoter A on IRES A activity. (A) Left: schema of the bicistronic constructs containing on the one hand either the
FGF1 Promoter A or the CMV promoter and on the other hand either the FGF1 IRES A or the EMCV IRES. Right: Diﬀerent promoter A
deletions were performed (1-391 and 1-682) and are schematized below the bicistronic construct. This latter series of constructs contains a more
recent version of ﬁreﬂy luciferase, Luc2CP, which displays higher expression than the classical ﬁreﬂy luciferase. (B) and (C). Activities of the FGF1
IRES A (B) and the EMCV IRES (C) obtained after transfection of C2C12 cells with the bicistronic constructs schematized in A (left). IRES
activities obtained in proliferating and diﬀerentiating myoblasts in the presence of promoter A (left panels) or CMV promoter (right panels) are
represented as LucF/LucR ratios. The activities are indicated above each histogram. Experiments were repeated at least three times. Results represent
means   standard errors from a representative experiment done in triplicate. (D) Transcriptional activities of the complete and deleted FGF1
promoter A in proliferating and diﬀerentiating myoblasts. Myoblasts were transfected with the bicistronic constructs described in Figure 7A (right)
and the LucR activities were measured. (E) Activities of the FGF1 IRES A in the diﬀerent constructs containing the complete or deleted FGF1
promoter A. IRES activities are given as the LucF/LucR ratio. The activities are indicated above each histogram. Experiments were repeated at least
three times. Results represent means   standard errors from a representative experiment done in triplicate.
Nucleic Acids Research, 2009,Vol.37, No. 16 5275are the most prominent FGF receptors in muscle
cells. FGFR4 has been recently shown to be strongly
up-regulated during myoblast–myotube transition (34).
Interestingly, Fgfr4
–/– mice show impaired muscle regen-
eration with slowed maturation of regenerating ﬁbers (34).
Translational regulation during myoblast differentiation
It has been well established that cap-dependent translation
is tightly regulated during the cell cycle (35,36). However,
little is known about translational control of gene expres-
sion during cell diﬀerentiation. Our work shows that
cap-dependent translation is repressed during myoblast
diﬀerentiation. This suggests that, at this stage, the
global translation is blocked in cells, whereas a small
number of mRNAs may be translated through cap-inde-
pendent mechanisms. This is the case for FGF1 whose
induction is not aﬀected by eIF4E sequestration, concom-
itant with the activation of its IRES A. Thus, our results
together with previous studies show that IRESs play a key
role in gene expression during diﬀerentiation of diﬀerent
cell types and during development (37–40).
The role of IRES in FGF1 expression was further con-
ﬁrmed in vivo during muscle regeneration. The importance
of IRES-dependent translation during muscle regenera-
tion has also been shown for utrophin A, a structural pro-
tein of the skeletal muscle ﬁber, mainly expressed at the
neuromuscular junction (41). In contrast to utrophin A,
FGF1 has no structural role, but a regulating function
during the myogenesis process. The importance of the
IRES-mediated translational control for two proteins
with such diﬀerent roles but both involved in the muscle
ﬁber regenerative response suggest that the IRES-depen-
dent process could drive expression of a subclass of
mRNAs whose coordinated induction would ensure the
success of the muscle regeneration process.
Coupling between transcription and IRES-dependent
translation
Among the four FGF1 alternative promoters, A and B
have been reported to be tissue-speciﬁc whereas C and
D are inducible (7,42). Our results reveal that promoter
A is active in skeletal muscle, and demonstrate its induci-
bility during myoblast diﬀerentiation. Interestingly, the
activity of IRES A, contained in the transcript generated
by promoter A, speciﬁcally increases during myoblast dif-
ferentiation and muscle regeneration.
Coordinated activation of IRES with the corresponding
promoter in conditions of cap-dependent translation
blockade has been reported for the Drosophila insulin-
like receptor, underlining the key role of IRESs in the
activation of gene expression when global translation is
silenced (43). The coupling of translation with transcrip-
tion shown in our study goes further by suggesting the
existence of a molecular mechanism of IRES A activation
depending on a cis-acting element in the promoter. One
could argue that the higher IRES A activity in the pres-
ence of promoter A could result from the weakness of this
promoter, whereas the strong CMV promoter would
result in mRNA overexpression and decreased IRES A
activity due to titration of a limiting ITAF. This was
proposed in a previous study showing that the c-myc
IRES is higher with the SV40 promoter than with the
CMV promoter (44). However, in our study, the strength
of the FGF1 promoter A is similar to that of the CMV
promoter (data not shown), and the deleted versions of
promoter A, which render the promoter very weak, are
not related to any IRES activation (Figure 7). This clearly
shows that the FGF1 promoter A has a positive eﬀect on
FGF1 IRES-driven translation. Our data suggest the exis-
tence of a translation–transcription coupling mechanism
requiring an element in the distal part of promoter A,
upstream from nt 392.
Such coupling of transcription with translation would
appear as a novel mechanism completing the complex net-
work of coupled interactions in gene expression proposed
by Maniatis and Reed (45). That model proposes coupling
of transcription with subsequent steps of mRNA proces-
sing and export, in gene expression factories anchored
to the nuclear substructure, where DNA is reeled through
the RNA polymerase as the nascent mRNA is extruded
through its exit channel. Such gene expression factories
contain all machineries involved in transcription, capping,
splicing and polyadenylation. Our data suggest that IRES-
dependent translation could also be controlled in these
gene expression factories, due to a co-transcriptional
‘loading’ of ITAFs on nascent mRNA. Consistent with
this hypothesis, most ITAFs identiﬁed so far are nuclear
or nucleocytoplasmic shuttling proteins implicated in a
staggering array of cellular activities, ranging from tran-
scription and pre-mRNA processing in the nucleus, to
cytoplasmic mRNA translation and turnover (46,47).
Interestingly, it has been shown that the same factor,
hnRNPK, controls the promoter and the IRES activities
of c-myc (48–50).
Such a direct coupling of transcription and IRES-
dependent translation despite the compartmentalization
of the cell nucleus might allow cells to respond more
quickly to environmental signals.
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